Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
The interplay between the intestinal microbiota and the brain.
BTG plc Close Period Update
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
The Inaugural Hillel Panitch, MD Multiple Sclerosis Symposium
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Thrombotic microangiopathy associated with interferon beta.
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Cognitive impairment in multiple sclerosis.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.

Pages